Tri-ing to decipher trisomy AML.

Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE

Publication: Oxford : Wiley-Blackwell
Original Publication: Oxford : Blackwell Scientific Publications

Trisomy* ; Leukemia, Myeloid, Acute*; Humans ; Prognosis ; Karyotyping

Lam et al. compared trisomy acute myeloid leukaemia (AML) patients (inclusive of single trisomy, double trisomy or tetrasomy cases) with cytogenetically normal AML to uncover distinguishing molecular and prognostic features of trisomy AML. The study contributes to our understanding of trisomy AML, but the heterogeneity of trisomy subtypes remains a barrier to its study. Commentary on: Lam et al. Distinct karyotypic and mutational landscape in trisomy AML. Br J Haematol 2024;204:939-944.
(© 2024 British Society for Haematology and John Wiley & Sons Ltd.)

Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an International Expert Panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-474.
Papaemmanuil E, Döhner H, Campbell PJ. Genomic classification in acute myeloid leukemia. N Engl J Med. 2016;375(9):900-901.
Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 ELN recommendations from an international expert panel. Blood. 2022;140:1345-1377.
Bhatnagar B, Eisfeld AK, Kohlschmidt J, Mrózek K, Nicolet D, Papaioannou D, et al. Clinical and molecular characterization of patients with acute myeloid leukemia and sole trisomies of chromosomes 4, 8, 11, 13 or 21. Leukemia. 2020;34(2):358-368.
Lazarevic VL, Rosso A, Juliusson G, Antunovic P, Derolf ÅR, Deneberg S, et al. Incidence and prognostic significance of isolated trisomies in adult acute myeloid leukemia: a population-based study from the Swedish AML registry. Eur J Haematol. 2017;98(5):493-500.
Lam ST, Pui S, Fung CY, Saw NY, Javed A, Ip H-W, et al. Distinct karyotypic and mutational landscape in trisomy AML. Br J Hematol. 2024;204:939-944.
Herold T, Rothenberg-Thurley M, Grunwald VV, Janke H, Goerlich D, Sauerland MC, et al. Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. Leukemia. 2020;34(12):3161-3172.
Shimony S, Garcia JS, Keating J, Chen EC, Luskin MR, Stahl M, et al. Molecular ontogeny in AML is both prognostic and predictive in patients treated with hypomethylating agents plus venetoclax. Blood. 2023;142(Suppl 1):977.
Döhner H, Pratz KW, DiNardo CD, Jonas BA, Pullarkat VA, Thirman MJ, et al. ELN risk stratification is not predictive of outcomes for treatment-Naïve patients with acute myeloid leukemia treated with venetoclax and azacitidine. Blood. 2022;140(Suppl 1):1441-1444.
Herold T, Metzeler KH, Vosberg S, Hartmann L, Röllig C, Stölzel F, et al. Isolated trisomy 13 defines a homogeneous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis. Blood. 2014;124(8):1304-1311.
Rainis L, Bercovich D, Strehl S, Teigler-Schlegel A, Stark B, Trka J, et al. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood. 2003;102(3):981-986.

Keywords: cytogenetic abnormalities; myeloid neoplasms; trisomy AML

Date Created: 20240108 Date Completed: 20240314 Latest Revision: 20240314

20240314

10.1111/bjh.19294

38190804